Now, in a new study published in the journal Cell, scientists at the Salk Institute for
Biological Studies have discovered that a synthetic form of vitamin D, calcipotriol (a drug already approved by the FDA for the
treatment of
psoriasis), deactivates the switch governing the fibrotic response in mouse liver cells, suggesting a potential new therapy for fibrotic diseases in humans.